It just might, according to this article in the Philly Enquirer (free registration req'd, and it's an annoying process, unfortunately). It basically says that pharma companies are rethinking their direct-to-consumer advertising strategies, now that ads for Vioxx and other related drugs have blown up in their faces as evidence for the potential for cardiac effects mounted.
[Mark Bard, president of Manhattan Research, a drug marketing consulting firm], said companies likely will shift ad dollars into alternative promotions, such as public-health programs or Continuing Medical Education programs for physicians. More companies may rely on the Internet to convey safety information, including clinical trial data, with the goal of counteracting public distrust fueled by Vioxx.
